mizoribine has been researched along with sulfasalazine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Arimura, K; Higuchi, I; Izumo, S; Kawabata, M; Kubota, H; Maruyama, Y; Nakagawa, M; Nakahara, K; Osame, M | 1 |
| Asano, G; Koda, M; Nakamura, H; Yoshino, S | 1 |
| Hanawa, H; Kobayashi, D; Kuroda, T; Murakami, S; Nakano, M; Narita, I; Oda, M; Wada, Y | 1 |
| Ito, S | 1 |
1 review(s) available for mizoribine and sulfasalazine
| Article | Year |
|---|---|
[DMARDs (Focusing on iguratimod)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cysteine; Drug Discovery; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Ribonucleosides; Sulfasalazine; Sulfonamides; Tacrolimus | 2016 |
1 trial(s) available for mizoribine and sulfasalazine
| Article | Year |
|---|---|
Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antiviral Agents; Ascorbic Acid; Azathioprine; Danazol; Erythromycin; Estrogen Antagonists; Female; Fosfomycin; Glycerol; Human T-lymphotropic virus 1; Humans; Hydrocortisone; Immunoglobulins, Intravenous; Immunosuppressive Agents; Injections, Intramuscular; Injections, Intravenous; Injections, Spinal; Interferon-gamma; Leukapheresis; Male; Methylprednisolone; Middle Aged; Paraparesis, Tropical Spastic; Pentoxifylline; Plasmapheresis; Propiophenones; Respiratory Therapy; Ribonucleosides; Sulfasalazine; Thyrotropin-Releasing Hormone; Vasodilator Agents | 1996 |
3 other study(ies) available for mizoribine and sulfasalazine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Effects of disease modifying antirheumatic drugs (DMARDs) and DEX on IL-1 beta and IL-6 production by IL-1 beta stimulated synovial culture cells].
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Cells, Cultured; Cysteine; Depression, Chemical; Dexamethasone; Gold Sodium Thiomalate; Humans; Interleukin-1; Interleukin-6; Methotrexate; Ribonucleosides; Sulfasalazine; Synovial Membrane; Tumor Necrosis Factor-alpha | 1996 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazoles; Biphenyl Compounds; Carbazoles; Carvedilol; Drug Therapy, Combination; Dyspnea; Etanercept; Female; Furosemide; Glucocorticoids; Hand; Heart Failure; Humans; Immunoglobulin G; Lung Diseases, Interstitial; Natriuretic Peptide, Brain; Propanolamines; Radiography; Receptors, Tumor Necrosis Factor; Rheumatoid Factor; Ribonucleosides; Scleroderma, Systemic; Spironolactone; Sulfasalazine; Tetrazoles; Treatment Outcome | 2011 |